Ready to hear about Oxy and whatever the other big generics are.
Many more potential positives/irons in the fire here for the company than potential negatives, IMO. Most products other than Adderrall IR (which is in shortage and in high demand) are relatively small but they are decently diversified overall. CEO anticipates increased sales of their ER version going forward with the company’s new sales and marketing arm.
But any newbie candidly shouldn’t trust anyone here - company website gives a quick overview of product offerings, read the filings, listen to, or read transcripts of, the conference calls.